Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositons comprising them and their use in the treatment of obesity
AssigneeAventis Pharma S.A.
InventorsOdile Piot-Grosjean, Philippe Picaut, Francois Petitet
Life of this patent
Estimating the term…
Abstract
The present invention relates to the combination of a CB1 receptor antagonist and of sibutramine, to the pharmaceutical compositions comprising them and to their use in the treatment of obesity.
Claims13
A combination of a CB1 receptor antagonist and sibutramine, its hydrate or one of its pharmaceutically acceptable salts, wherein the CB1 receptor antagonist is:
- 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene] azetidine, or a pharmaceutically acceptable salt thereof.
A composition comprising a CB1 receptor antagonist and sibutramine, its hydrate or one of its pharmaceutically acceptable salts, wherein the CB1 receptor antagonist is:
- 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene] azetidine, or a pharmaceutically acceptable salt thereof.
A process for treating obesity in a mammal, comprising administering to the mammal in need thereof an effective amount of at least one CB1 receptor antagonist and sibutramine, its hydrate or one of its pharmaceutically acceptable salts, wherein the CB1 receptor antagonist is:
- 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene] azetidine, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.